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Background: The conventional treatment for Dupuytren’s disease is surgery. The introduction of alternative
treatment strategies creates a need to track outcomes and costs relating to surgical treatment and risk factors, such
as smoking and diabetes. This was the aim of the present study.
Methods: In a prospective study, the outcome of open surgical treatment for finger flexion contracture in
Dupuytren’s disease (175 patients; 182 surgical procedures) was studied by evaluating valid QuickDASH forms
answered by subjects before surgery and one year postoperatively. Data were also obtained from medical records,
and preoperative declarations concerning health.
Results: In all subjects (median [25% - 75% percentiles] age 68 [62-73]), the QuickDASH score improved from 22
[9-36] to 5 [0-18]. Smokers (27/179 procedures) were younger and had a more severe degree of disease and
dysfunction preoperatively than non-smokers, but the outcome of surgery did not differ between the groups.
Subjects with diabetes (20/181 procedures) were younger than those without diabetes, but their disease severity or
outcome did not differ. Hand specialists operated faster than residents, but the surgical outcome did not differ.
Healthcare costs for surgery for Dupuytren’s contracture were $ 2392 (€ 1859), which were not higher among
smokers or subjects with diabetes. Only 22 patients remained in hospital (2 [1-2.3] days) and 28 patients needed sick
leave (28 [21-31] days). The occurrence of necrosis of skin flaps (12%) or infections (6%) was no more frequent
among smokers or those with diabetes.
Conclusions: There is no difference in surgical outcome for finger flexion contracture in Dupuytren’s disease
between smokers and non-smokers or between subjects with or without diabetes, although smokers had more
severe preoperative contracture. The costs for surgical treatment for finger flexion contracture in Dupuytren’s
disease should be viewed in relation to that for other treatment strategies.
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Dupuytren’s disease is a condition that affects various
parts of the palmar aponeurosis in the hands, but it can
also occur in the sole of the foot and in the penis. The
disease results in a progressive formation of nodules and
cords in the palm leading to a flexion contracture, usu-
ally affecting the metacarpophalangeal (MCP-) and prox-
imal interphalangeal (PIP-) joints in the fingers involved* Correspondence: lars.dahlin@med.lu.se
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unless otherwise stated.[1]. Flexion contracture may have a great impact on
daily living due to the functional difficulties, e.g. diffi-
culty in washing the face or putting on gloves [2].
Dupuytren’s disease has a genetic component [3] and
can manifest with varying severity. It commonly affects
men, however, women also often present, but with a dif-
ferent disease character, such as isolated contracture of
the pip-joint in the little finger, and may also have a later
disease onset [4]. There is a higher prevalence of Dupuyt-
ren’s disease in a population of subjects with diabetes,
while impaired glucose tolerance (IGT) does not seem to
increase the prevalence of the disease [5], although thisl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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may have a higher incidence of postoperative complica-
tions [6] and the outcome of surgery in such patients has
been barely studied. Smoking has also been a contested
factor in Dupuytren’s disease, with some studies showing
a correlation between the occurrence of Dupuytren’s dis-
ease and smoking [7], but again the outcome of surgery in
smokers has not been particularly emphasized.
Treatment of Dupuytren’s disease to date has been
open surgery (e.g. partial fasciectomy, fasciotomy, der-
mofasciectomy or amputation) and in some parts of
Europe, e.g. France and the Nordic countries, the more
unusual percutaneous needle fasciotomy is performed
[8,9]. Over recent years a new pharmacologic treatment,
injection of a collagenase into the fibrous cords with a
subsequent “pop up” procedure to break the Dupuytren’s
disease cord, has become available and is now com-
mon, despite being more expensive than percutaneous
needle fasciotomy [9,10]. A recurrence of Dupuytren’s
disease after treatment is common, and is a result of
the method of treatment [11,12]. The costs and resources
required for various surgical treatments have not so far
been evaluated.
Our purpose was to evaluate the outcome, assessed
using the QuickDASH questionnaire [13], of surgical
treatment of Dupuytren’s disease as well as the severity
of the preoperative flexion contracture in relation to the
risk factors of smoking and diabetes. In addition, the
healthcare costs for various components of the treat-
ment, such as pre- and post-operative outpatient visits,
open surgery, rehabilitation and medical treatment by
nurses, were evaluated. Such costs are important in view
of the recent introduction on the market of a pharmaco-
logical substance to treat finger flexion contracture in
subjects with Dupuytren’s disease [9].
Methods
In this prospective study, subjects treated for finger
flexion contracture due to Dupuytren’s disease, at the
Department of Hand Surgery, Skåne University Hospital,
Malmö, Sweden between September 2009 and February
2011, were identified by searching the administrative
records for the diagnosis code Dupuytren’s contracture
(ICD 10 code M72.0).
Subjects treated surgically during this time period
were routinely provided with the QuickDASH form to
be filled in before and one year after the surgical pro-
cedure. A Swedish translation of the form, including
eleven questions measuring daily life symptoms and func-
tion of the arm, was used. Each question was judged by
the patient from 1 (no disability) to 5 (great disability).
The total score was calculated and varied between zero
and 100. At least ten questions had to be answered for the
form to be valid [13,14].In addition, healthcare costs for various treatments, such
as outpatient or surgery visits, rehabilitation, and treatment
by nurses, were estimated. Lengths of hospital stay and
sick leave were calculated among the subjects who were
admitted to the hospital and those still in the labour mar-
ket, respectively.
Subjects
To be included, subjects had to be surgically treated for
finger flexion contracture due to Dupuytren’s disease be-
tween September 2009 and February 2011 and to have
completed a valid QuickDASH form both before and
one year after surgery. Subjects who were operated on
primarily for another main disorder of the hand were ex-
cluded. Subjects were divided according to whether they
underwent an open surgical procedure or a percutaneous
procedure. Only subjects who had an open surgical pro-
cedure were included (n = 182). Subjects with procedures,
such as arthrodesis or amputations, were excluded.
Preoperative information was registered from the sub-
jects’ declaration on the health form, which is routinely
collected before surgery, while other pre- and post-
operative data were obtained from the medical records of
the subjects. Additional data, such as age, gender, body
mass index (BMI), disease severity (i.e. finger flexion con-
tracture), duration of surgical procedure, presence of post-
operative infections and or necrosis of skin flaps (including
delayed healing), were also collected. Three subjects were
excluded due to insufficient information obtainable from
the records. When available, the preoperative QuickDASH,
as well as the above information, were also collected
from the records of those subjects who had been ex-
cluded because of the lack of or an invalid postopera-
tive QuickDASH. Thus, allowed comparison between
excluded and included patients.
The severity of the finger flexion contracture due to
Dupuytren’s disease was graded based on the extension
deficit of the subject. The following revised model of the
Tubiana staging system was used:
Stage 0: no lesion, healthy
Stage N: palmar or digital nodule without established
flexion deformity
Stage Ia: total flexion deformity between 0° and 20°
Stage Ib: total flexion deformity between 21° and 45°
Stage II: total flexion deformity between 45° and 90°
Stage III: total flexion deformity between 91° and 135°
Stage IV: total flexion deformity exceeding 135° (7).
Calculation of costs for treatment
The costs for treatment were calculated using the fol-
lowing figures (Prices from Skåne University Hospital;
2012; exchange rate for US dollar ($) and Euro (€) calcu-
lated from mean value from 2012): $20 (€ 16) for each
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with the surgeon, $ 75 (€ 58) for each visit to the re-
habilitation unit or to the nurses at the outpatient clinic
and $ 513 (€ 397) for each day spent on the ward.
Statistical methods
Values are presented as median [IQR; 25 – 75 percen-
tiles]. Nominal data are shown as numbers (%). The chi-
square and the Mann-Whitney tests were used to detect
any significant differences between groups. P-values <
0.05 were considered statistically significant. IBM SPSS
Statistics, version 20 for Mac and StatView for Windows
(SAS institute Inc., version 5.0.1, Cary NC, USA) were
used for all calculations.
Ethical considerations
The present project, and those with similar design, is not
covered by the law (2003:460) in Sweden - “The ethical
review of research involving humans” – according to the
Ethical Review Board in Lund and no advertising is needed.




During the period covered by the study 268 patients at
the department received any treatment primarily for
Dupuytren’s disease in the form of any procedure to cor-
rect finger flexion contracture due to the disease. In total
288 different procedures were performed. In three of these
patients/procedures no data were found or recorded in
the subjects’ medical records. Thus, three subjects were
not available for analyses, resulting in a selected group of
265 patients and 285 procedures.
A valid QuickDASH form was completed by 195 sub-
jects (74%) and was available for 202 of the proce-
dures (71%). Seven of the 20 bilaterally treated subjects
handed in a valid QuickDASH form for both hands.
Thus, the group of subjects that could tentatively be
studied comprised 202 procedures (i.e. 171 fasciectomies,
eleven fasciotomies, ten percutaneous needle or knife
fasciotomies and six amputations/arthrodesis; 4 unknown
procedure).
Included subjects with preoperative and postoperative
valid QuickDASH
Most of the subjects had an open surgical procedure;
i.e. 182/202 (90%) of the selected procedures were open
surgery (i.e. open fasciectomies or open fasciotomies);
16 (8%) procedures were either a percutaneous needle
or knife fasciotomy or an amputation/arthrodesis; in
the remaining four (2%) procedures the method of treat-
ment was unknown. Patients with amputation/arthrodesis
were too few to be included in the open surgery groupand were also interpreted as having a procedure differ-
ent from partial fasciectomy and open fasciotomy; thus
were excluded from the open procedures and the number
of procedures included were n = 182.Characteristics of all included subjects and results of
open surgery
The characteristics of the included subjects/surgeries are
presented in Table 1. Among the 182 open procedures
(i.e. open fasciectomies and fasciotomies), most were
performed in men (median age 68 years). In 80 (44%) of
these procedures, the subject had a BMI > 25, classified
by WHO as overweight [15]. Twenty of the procedures
were performed in subjects with type 1 (10%) or type 2
(85%) diabetes (5% had an unknown type of diabetes; in
one patient information about glucose status was lacking).
Eighty-three (46%) procedures were performed in subjects
who were receiving pharmacological treatment for hyper-
tension and the subjects in 36 (20%) procedures were be-
ing treated with statins. In 27 (15%) of the procedures, the
subjects reported that they were smokers (i.e. information
about smoking was lacking in three patients).
In the group that underwent open surgery (n = 182), both
pre- and post-operative Tubiana staging was available for
121 (66%) procedures. Preoperative Tubiana staging was
present in 160 (88%) subjects, while 131 (72%) had post-
operative Tubiana staging; thus, 14 (8%) of the subjects
had no measurements. In most of the procedures, the sub-
jects had the preoperative Tubiana stage “2” [n = 81 (45%)].
The Tubiana stage improved after surgery to 1b [n = 49
(27%)]; although postoperatively only 6% of the measured
fingers had a Tubiana stage of “2” or higher. The median
improvement in Tubiana score was 3 [2-4] stages. The ex-
tension deficit decreased considerably (Table 1). In 21
(12%) of the procedures, skin necrosis or delayed healing
after surgery was observed to some extent. In 11 (6%) of
the procedures, the subject was treated for a superficial in-
fection in the wound.Outcome after open surgery among all included (n = 182)
subjects
The scores of the QuickDASH pre- and post-operative
(n = 182), as well as the change (including those with a
postoperative score of >10 and a change < 10), are shown
in Table 2. QuickDASH scores decreased after surgery
among subjects in the whole population. In most of the
182 open procedures included, subjects had a postopera-
tive change > 10 in QuickDASH score and most had a
remaining QuickDASH scores < 10. Both these criteria are
considered to be crucial in evaluating outcome, where
change of more than > 10 is considered the minimal sig-
nificant change and a postoperative score > 10 indicates
remaining disability [16,17].








diabetesb (n = 161)
Subjects with
diabetesb (n = 20)
p-value
Age 68 [62-73] 70 [64-75] 63 [59-67] 0.001 69 [63-74] 63 [59-70] 0.03
Gender Male (78%) Male (75%) Male (93%) 0.04 Male (79%) Male (80%) 0.83
BMI 25.1 [23.4-27.1] 25.1 [23.4-27.1] 25.3 [23.1-26.8] 0.87 24.9 [23.1-26.8] 26.8 [23.7-28.9] 0.06
Hypertension
(treated) (%)
46% 46% 41% 0.71 42% 75% 0.001
Statin treatment (%) 20% 20% 19% 0.88 17% 40% 0.0001
Preoperative flexion
contracture (degrees)
90 [60-110] 85 [60-105] 98 [79-143] 0.04 90 [60-110] 80 [63-113] 0.95
Postoperative flexion
contracture (degrees)
20 [0-35] 20 [0-30] 30 [11-40] 0.12 20 [0-35] 20 [15-35] 0.57
Improvement
(degrees)
65 [45-87] 60 [45-85] 78 [40-91] 0.60 65 [45-90] 60 [45-80] 0.55
Preoperative
Tubiana stage
1b [20 (11%)] 1b [19 (12%)] 1b [1 (4%)] 0.09 1b [19 (12%)] 1b [1 (5%)] 0.97
2 [81 (45%)] 2 [69 (45%)] 2 [10 (37%)] 2 [70 (43%)] 2 [10 (50%)]
3 [41 (22%)] 3 [36 (24%)] 3 [5 (18%)] 3 [37 (23%)] 3 [4 (20%)]
4 [18 (10%)] 4 [12 (8%)] 4 [6 (22%)] 4 [16 (10%)] 4 [2 (10%)]
Unknown [22 (12%)] Unknown [16 (11%] Unknown [5 (19%)] Unknown [19 (12%)] Unknown [3 (15%)]
Postoperative
Tubiana stage
0 [34 (19%)] 0 [29 (19%)] 0 [4 (15%)] 0.66 0 [31 (19%)] 0 [3 (15%)] 0.98
1a [37 (20%)] 1a [33 (22%)] 1a [4 (15%)] 1a [32 (19%)] 1a [5 (25%)]
1b [49 (27%)] 1b [38 (25%)] 1b [11 (41%)] 1b [43 (27%)] 1b [6 (30%)]
2 [10 (5.5%)] 2 [9 (6%)] 2 [1 (4%)] 2 [9 (6%)] 2 [1 (5%)]
3 [1 (0.5%)] 3 [1 (1%)] 3 [0 (0%)] 3 [1 (1%)] 3 [0 (0%)]
4 [0 (0%)] 4 [0 (0)] 4 [0 (0%)] 4 [0 (0%)] 4 [0 (0%)]
Unknown [51 (28%)] Unknown [42 (28%)] Unknown [7 (26%)] Unknown [45 (28%)] Unknown [5 (25%)]
Values are median [25% - 75% percentiles], numbers (%) or %. aInformation about smoking was lacking in three patients. bInformation about glucose status was
lacking in one patient.
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preoperative or postoperative QuickDASH
In 83/285 procedures (i.e. no data in patient folder in
three procedures), the subjects did not hand in two valid
QuickDASH forms and were thus excluded from the
study. Of these, 34 (41%) had a valid preoperative Quick-
DASH. There were no significant differences between






Preoperative QuickDASH (total score) 22 [9-36] 21 [9-34]
Postoperative QuickDASH (total score) 5 [0-18] 5 [0-16]
Change in QuickDASH (total score) 11 [2-24] 10 [2-22]
Postoperative QuickDASH > 10
(numbers; %)
65 (36%) 53 (35%)
Change in QuickDASH total score < 10
after surgery (numbers; %)
74 (41%) 65 (43%)
Values are median [25% - 75% percentiles] or numbers (%). aInformation about smo
lacking in one patient.The data of the excluded subjects are not included in
other parts of the Results (below) or in any of the
Tables.
Surgically treated smokers and non-smokers
The characteristics of the subjects and the outcomes after
open surgical procedure in smokers and non-smokers are




diabetesb (n = 161)
Subjects with
diabetesb (n = 20)
p-value
30 [14-43] 0.04 21 [9-36] 30 [7-43] 0.25
5 [0-25] 0.90 5 [0-18] 7 [2-17] 0.48
11 [5-25] 0.29 11 [2-23] 10 [3-30] 0.58
11 (41%) 0.56 57 (35%) 7 (35%) 0.40
8 (30%) 0.20 64 (40%) 9 (45%) 0.43
king was lacking in three patients. bInformation about glucose status was
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worst affected finger was more severe in smokers than in
non-smokers. However, the preoperative extension deficit,
as evaluated by Tubiana scoring, did not differ between
the two groups.
As shown in Table 2, smokers had higher preoperative
QuickDASH scores compared to non-smokers. Postop-
eratively, there were no significant differences in any
outcome variables between smokers and non-smokers.
However, there was a significant difference in the length
of stay on the ward, with the smokers having a shorter
stay than the non-smokers (Table 3). There was no dif-
ference between smokers and non-smokers in postoper-
ative occurrence of skin necrosis or infections [16 (11%)
and 5 (19%); p = 0.23, respectively] or infections [9 (6%)
and 2 (7%); p = 0.77, respectively].
Surgically treated subjects with and without diabetes
The characteristics of the subjects and the outcomes of
open surgery among those with and without diabetes are
presented in Tables 1 and 2. The subjects with diabetes
were younger than the patients without diabetes, while
BMI did not differ significantly. As expected, the pres-
ence of treated hypertension differed significantly be-
tween patients with and without diabetes being more
common in subjects with diabetes, and a similar pattern
was also observed for treatment with statins. There were
no differences between subjects with or without diabetes
in the postoperative occurrence of skin necrosis [19
(12%) and 2 (10%); p = 0.81, respectively] or infections
[10 (6%) and 1 (5%); p = 0.83, respectively].
There were no significant differences between subjects
with and without diabetes in pre- or post-operative se-
verity of flexion contracture or in improvement after
surgery expressed in degrees. Furthermore, the Tubiana
stages did not differ between the two groups. In addition,







Duration of operation (min) 77 [56-102] 74 [56-103] 86
Appointments with the
surgeon (numbers)
3 [2-4] 3 [2-4]
Appointments with hand
therapist (numbers)
2.5 [0-5] 2 [0-5] 3
Appointments with nurse (numbers) 1 [0-1] 1 [0-1] 1
Sick leave (days)1 28 [21-31] 28 [21-31] 2
Duration of hospital stay (days)2 2 [1-2.3] 2 [2-3]
Values are median [25% - 75% percentiles]. aInformation about smoking was lackin
one patient.
1Only from those procedures when subjects were sick listed.
2Only for those procedures when the subject was admitted to a ward.between the groups. Finally, no other healthcare variables
differed (Table 3).
Costs and resources in surgically treated subjects
A specialist in hand surgery performed 65% [n = 118]
of the procedures, while a resident did fewer [n = 62
(34%)]. The duration of surgery performed by specialists
was 10 minutes shorter, but there were no differences in
any variables or outcomes between subjects operated on
by a specialist or a resident.
Data for resources, without costs, of included patients
(n = 182) are shown in Table 3 and costs are presented
here. The median duration of the surgical procedure in
all the patients resulted in an individual median cost of
$ 1572 (€ 1222). Appointments with the surgeon in-
curred a median cost of $ 557 (€ 433) in each subject.
Visits to the rehabilitation unit resulted in a median cost
of $ 188 (€ 146), while treatments by a nurse resulted in
a median cost of $ 75 (€ 58). Thus, the median total
health care cost was $ 2392 (€ 1859) for each subject in
the total population. Most subjects were day-case proce-
dures [n = 151 (83%)]. Those who were admitted [n = 22
(12%); 2 (1-2.3) nights] incurred in a median additional
cost of $ 1022 (€ 795) per subject. Thus, the total health-
care cost for admitted subjects was $ 3414 (€ 2654).
Most procedures were performed on subjects who were
retired [n = 123 (68%)]. The subjects who needed sick
leave [n = 28 (15%)] spent 28 [21-30.8] days off work,
which resulted in an income loss of $ 4303 (€ 3345) per
subject on sick leave.
Discussion
The present data clearly indicate that open surgery has a
favourable effect for finger flexion contracture in Dupuytren’s
disease at one-year post surgery. In addition, the data con-
cerning characteristics of the subjects are consistent with




diabetesb (n = 161)
Subjects with
diabetesb (n = 20)
p-value
[55-108] 0.22 79 [57-102] 68 [52-101] 0.28
3 [2-3] 1.00 3 [2-4] 2 [2-3] 0.18
[0-5.5] 0.32 2 [0-5] 3 [0-4.3] 0.95
[0.3-1] 0.33 1 [0-1] 1 [0.3-1] 0.27
8 [21-37] 0.94 28 [21-31] 30 [28-34] 0.27
1 [1-1] 0.01 2 [2-3] 1 [1-1.8] 0.11
g in three patients. bInformation about glucose status was lacking in
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context. However, one should keep in mind that recur-
rences are common after surgical treatment of finger
flexion contracture in Dupuytren’s disease [12]; an aspect
that is not addressed or was an aim in the present study.
The present study also reveals that smokers, who were
younger than non-smokers, were treated at a more severe
stage of the disease, but smoking as a risk factor did not
have any negative impact on the outcome of the surgical
treatment of finger flexion contracture in Dupuytren’s dis-
ease. Furthermore, subjects with diabetes were also youn-
ger than those without diabetes, but again the outcomes
did not differ. Specialists in hand surgery operated ten mi-
nutes faster than residents, but outcomes after open sur-
gery were no different, irrespective of the presence of the
risk factors smoking or diabetes among the subjects.
Smoking and surgical treatment of finger flexion
contracture in Dupuytren’s disease
In our study, 15% of the patients were smokers, which
correlates well with a larger European study in which
the number of smokers with Dupuytren’s disease in the
Nordic region was 18% [18]. In the rest of Europe, per-
centages of smokers with Dupuytren’s disease differ
widely, i.e. 41-49% smokers [18]. Interestingly, the data
in that European survey also indicate that the stage of
Dupuytren’s disease in the treated subjects was more se-
vere in the Nordic countries, which is consistent with a
tradition that the indication for surgery in the Nordic re-
gion is a more advanced Tubiana stage or even that
smoking speeds up the progression of the disease.
The effects of smoking on Dupuytren’s disease are con-
tested [7,19]. The present data indicate that smokers are
treated at a later stage of Dupuytren’s disease, but we have
no explanation for this observation. It may be caused by
factors related to the subjects, i.e. individual factors or a
direct pathophysiological mechanism(s), or to the sur-
geons, or both. The smokers had a higher preoperative
QuickDASH score, although they were younger than
the non-smokers. One may speculate that Dupuytren’s
disease develops earlier in smokers than in non-smokers;
thus, smoking may be a risk factor for development of
finger flexion contracture in Dupuytren’s disease. In
one study, where a connection between Dupuytren’s
disease and smoking was shown, the risk was adjusted
for age [7]; we did not make any adjustments of that sort
in our study. Nevertheless, there were no significant differ-
ences in postoperative QuickDASH score or in im-
provement of QuickDASH score between smokers and
non-smokers, indicating that open surgical treatment can
be performed later without jeopardizing the outcome, the
postoperative Tubiana score or the extension deficit. In
addition, the present smokers did not have a higher per-
centage of complications, such as necrosis of skin flaps(including delayed healing) or infections, but one cannot
entirely exclude the possibility that the limited number of
subjects in the present study may have precluded the de-
tection of any difference in complications. Therefore, the
present findings should be interpreted with some caution
and the results should be confirmed in larger populations
from national registries.
Diabetes and surgical treatment of finger flexion
contracture in Dupuytren’s disease
Dupuytren’s disease is more frequently seen in subjects
with type 2 diabetes [5], but the disease may be less se-
vere and progress more slowly in subjects with diabetes
than in healthy subjects [1]. Our treated subjects with
diabetes were younger indicating, in accordance with
other studies [1], that the disease occurs earlier in sub-
jects with diabetes. The percentage of the present sub-
jects with diabetes, consisting mainly of subjects with
type 2 diabetes, was 11%, which was lower than in the
European survey (17% in Nordic countries and 26-36%
in the rest of Europe [18]), and implies that fewer subjects
with diabetes are treated surgically at our department.
However, there were no differences in any outcome vari-
ables between the subjects with and without diabetes, ex-
cept that subjects with diabetes were younger. Again, this
may indicate that Dupuytren’s disease develops earlier in
patients with diabetes, but a favourable outcome is still to
be expected. Subjects with diabetes may have a higher in-
cidence of postoperative complications [1], but this is in
contrast to our study results. Taken together, our results
imply that despite an earlier development of the disease,
diabetes does not impact the outcome of surgical treat-
ment of finger flexion contracture in Dupuytren’s disease.
This is notable in view of an estimated global increase in
the number of subjects with diabetes and thus an expected
worldwide increase in the need for treatment of Dupuyt-
ren’s disease in subjects with diabetes.
Resources and costs for surgical treatment of finger
flexion contracture in Dupuytren’s disease
The costs, if the subject was admitted, were higher [$ 2392
(€ 1859) compared to $ 3414 (€ 2654)] than if the proced-
ure was performed as outpatient surgery. The length of
stay at the ward in subjects who were admitted differed
from that for northern Europe in general (i.e. one night),
while it is longer in other parts of Europe [18]. A reduction
in the number of unnecessary days on the ward may re-
duce costs for the healthcare system since admission to a
ward in connection with a surgical treatment is expensive
and resource intensive, which is an important point in view
of a lower financial support to hospitals and an increased
population globally. However, admission to a ward may be
required if the procedure is a reoperation with a risk of
surgical complications, or the subject has a complicated
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Interestingly, smokers had a shorter stay at the ward and
thus potentially lower costs. Finally, some of the treated
subjects were still on the labour market and needed sick
leave after the surgery, resulting in a loss of production;
thus, a further cost for the society. The loss of production
should be taken into account when considering the treat-
ment of choice for a patient with finger flexion contrac-
ture due to Dupuytren’s disease in view of the shorter
rehabilitation after percutaneous needle fasciotomy or
pharmacological treatment (i.e. collagenase injections) of
the contracture, but with the risk of a faster recurrence
after the latter two procedures than after open surgical
treatment. One should also consider the costs for collage-
nase treatment; i.e. costs for one vial of drug $ 951 (€ 739)
in Sweden. It has been estimated that the average pa-
tient needs to treat 1.2 fingers with collagenase (per-
sonal communication Pfizer Inc., Sweden), which will
result in a total costs for treatment of $ 1768 (€ 1374)
[i.e. 1.2 fingers × (two outpatient visits + two visits to re-
habilitation unit + cost collagenase vial) = total costs for
collagenase treatment]. In accordance, the costs for a
percutaneous needle fasciotomy would be $ 522 (€ 405)
[i.e. one extended (x2) outpatient visit and two visits to
rehabilitation unit]. However, the complexity of the dis-
ease, with various severity of the disease, makes it difficult
to judge the exact costs for treatment in a simple way [20],
since the recurrence after collagenase treatment and percu-
taneous needle fasciotomy may be faster than after surgery,
which should be taken into account. Surgery may also re-
quire admission to a ward in some patients, where the other
two procedures can be performed as outpatient procedures.
The surgical procedures that were performed by a spe-
cialist took 10 minutes less than those done by residents,
but the pre- or post-operative clinical status did not differ,
indicating that the severity of the Dupuytren’s disease was
similar in the patients treated. In addition, the outcomes
did not differ with respect to QuickDASH scores or im-
provement. These results are interesting from a cost point
of view as well as logistically. One may suggest that more
surgical procedures on cases of Dupuytren’s disease could
be performed by residents, freeing more time for special-
ists to deal with more severe cases, but without jeopardiz-
ing outcomes.
Limitations of the study
The data concerning the number of treatment sessions
by nurses, physiotherapists and occupational therapists
may possibly be an underestimation, since the data re-
corded in the medical charts may be incomplete and
such categories of staff may have treated some subjects
outside the department. A similar limitation, related to
an underestimation of the costs, is that we had no infor-
mation about how many outpatient visits the subjectsmade to their GP before referral, but approximately half
of the subjects were referred from a GP. Around 10% of
the subjects also wrote “their own referral letter” because
of their symptoms and limitations on their activities due
to finger flexion contracture caused by Dupuytren’s dis-
ease. The rest of the subjects were or had been treated for
another hand condition at the department. Therefore, we
could not with 100% certainty calculate the costs that in-
cluded pre-referral costs. However, these are probably low
in comparison with the treatment costs; i.e. total costs for
treatment consisting of a) health care costs (e.g. outpatient
visits to surgeon, nurses and hand therapists) and b) loss
of production (e.g. sick-leave).
Another limitation is the time period (i.e. one-year fol-
low up) during which the subjects were collected. Had
the time period for data collection been longer a more
accurate evaluation of costs could have been made.
However, forms with declarations of health together with
QuickDASH data were only available during the selected
time period. Thus, in future it would be interesting to
evolve the study to include a longer time period with
more subjects, including a 100% cover of e.g. Tubiana
staging, and additional relevant information about other
treatment options, such as percutaneous needle fasciot-
omy or pharmacological treatment (i.e. collagenase in-
jections). Such a focus, including long-term recurrence
of the disease and contracture, could be achieved by
assessing national registries to include a large number of
subjects nationally (http://www.hakir.se).
The final limitation is that we used the generic assess-
ment scale QuickDASH for evaluation of the treatment.
Finger flexion contracture in Dupuytren’s disease has a
distinct impact on the patients’ activities and quality of
life [2] and at present there is no suitable assessment
scale that is specific for this disease. We, therefore, used
the QuickDASH questionnaire to evaluate the outcome
of surgery. However, in the near future a specific scale
for evaluating the outcomes of various treatment strat-
egies will be developed [2].
Conclusions
Surgical treatment is favourable in subjects with Dupuyt-
ren’s finger flexion contracture. The outcomes of surgi-
cal treatment of Dupuytren’s contracture, including the
frequency of complications, such as skin necrosis and in-
fections, do not differ between smokers and non-smokers
or between subjects with or without diabetes, although
the preoperative finger flexion contracture was more
severe in the former. Furthermore, smokers and subjects
with diabetes were younger, which may indicate a tendency
to develop Dupuytren’s disease earlier. The costs for surgi-
cal treatment of finger flexion contracture in Dupuytren’s
disease should be seen in perspective in relation to the
price of other treatment strategies.
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